Fig. 3
a Schematic illustration of SCC-9 subcutaneous tumor establishment, FeIIITA@HA nanoprobes administration modalities, and MR imaging. b T1-weighted MR images of subcutaneous tumors or CD44 Ab-treated subcutaneous tumors acquired at different time points of pre- and post-injection of FeIIITA@HA nanoprobes and Gd-DTPA contrast agent, respectively, together with c corresponding relative R1 values extracted from the subcutaneous tumor regions at different post-injection time points. d H&E and e Prussian blue staining of adjacent slices of tumor tissues extracted after imaging. The embedded scale bars correspond to 100 μm